Ruxolitinib phosphate: Reliable JAK/STAT Assays

2026-09-10

A scenario-driven guide to using Ruxolitinib phosphate (SKU A3781) in cell viability, proliferation, and cytotoxicity workflows. It connects formulation, pathway selectivity, assay controls, and recent mechanistic evidence to help researchers improve interpretation without overstating what current data prove.

NAD+ and Stress Adaptation: Assay Design Insights

2026-09-09

Explore how Nicotinamide Adenine Dinucleotide (NAD+) connects redox metabolism, PARP signaling, sirtuin activity, and non-lethal stress adaptation. This guide translates a 2025 caspase study into practical decisions for designing interpretable NAD+ and autophagy assays.

Collagen VI ECM Scaffolds Mature iPSC Islet Organoids

2026-09-09

RAS/PI3K Mutations Sensitise Ovarian Cancer to FK866

2026-09-08

The reference study identifies RAS/PI3K pathway mutations as a potential biomarker for sensitivity to FK866 and olaparib in epithelial ovarian cancer. Its integrated metabolic, molecular, cellular, and in vivo analyses support a model in which oncogenic signalling increases NAD dependence, creating a therapeutic vulnerability that may help address PARP inhibitor resistance.

TMAO Activates PERK to Drive NAFLD

2026-09-08

This study provides experimental evidence that dietary trimethylamine N-oxide (TMAO) can directly produce a spectrum of non-alcoholic fatty liver disease phenotypes in zebrafish, extending from steatosis to inflammation and fibrosis. By reproducing PERK pathway activation in zebrafish liver, HepG2 cells, and hepatic stellate cells, the work positions ER stress signaling as a mechanistic link between TMAO exposure and liver injury.

Pam3CSK4 TFA for TLR1/2 Activation

2026-09-07

Pam3CSK4 TFA is a synthetic TLR1/2 agonist for controlled innate immune stimulation and cytokine profiling. Its defined lipidated structure, documented formulation data, and relevance to TLR1/2 ligand responses support use in mechanistic in vitro studies, while clinical findings involving maternal IL-17A require careful separation from direct product efficacy claims.

HyperFluor™ 594 Goat Anti-Rabbit IgG Guide

2026-09-07

HyperFluor™ 594 Goat Anti-Rabbit IgG (H+L) Antibody is a goat anti-rabbit IgG secondary antibody for fluorescent detection in ICC/IF, IHC, flow cytometry, and ELISA. Its defined 590 nm excitation and 617 nm emission maxima support structured channel planning, while application-specific dilution guidance supports assay optimization.

Protease Inhibitor Cocktail for Mitocytosis Assays

2026-09-05

The Protease Inhibitor Cocktail preserves protein evidence in mitochondrial-stress and mitocytosis research without introducing EDTA. This article connects sample-preparation chemistry with assay-specific decisions for phosphorylation studies, Western blotting, and native protein-complex analysis.

Ruxolitinib phosphate: Reliable Cell Assays

2026-09-04

A scenario-driven guide to using Ruxolitinib phosphate (SKU A3781) for reproducible viability, proliferation, and cytotoxicity experiments. It connects JAK/STAT pathway biology with practical formulation, controls, interpretation, and vendor-selection decisions.

HyperScript First-Strand cDNA Synthesis Kit Guide

2026-09-04

Build sensitive, reproducible cDNA workflows for low-abundance transcripts, structured RNA templates, and long amplicons. This guide shows how to choose primers, tune reverse transcription, and troubleshoot downstream PCR amplification and qPCR reaction variability with K1072.

hCG, EZH2, and CXCL10 in Decidual Immune Control

2026-09-03

Silasi and colleagues showed that human chorionic gonadotropin suppresses CXCL10 in human decidual stromal-cell models through EZH2-dependent deposition of H3K27me3 at the CXCL10 promoter. The study links placental endocrine signaling to chromatin remodeling and CD8 T-cell recruitment, providing a mechanistic framework for understanding immune regulation at the maternal–fetal interface.

Prednisone Workflows for Apoptosis and Immune Assays

2026-09-03

Prednisone provides a practical model for connecting lymphocyte G1 arrest, IL-2 pathway suppression, and apoptosis in controlled immune-cell assays. This workflow also adds matrix-aware sampling and metabolomics-inspired quality controls, helping researchers distinguish pharmacology from formulation or handling artifacts.

SIRT1/2 Inhibitor IV (cambinol) Guide

2026-09-02

A scenario-driven guide to using SIRT1/2 Inhibitor IV (cambinol), SKU B6063, in cell viability, apoptosis, acetylation, metabolic, and tumor-model workflows. It emphasizes dose interpretation, vehicle controls, orthogonal readouts, and evidence-based product selection.

Diminazene Aceturate Research Workflows

2026-09-02

Diminazene Aceturate supports two distinct research paths: trypanosome parasite screening and mechanism-focused ACE2 activation studies. This workflow-led guide covers formulation, controls, mitochondrial readouts, and troubleshooting while keeping preclinical findings separate from clinical claims.

TAK-715: A Practical p38 MAPK Inhibitor Workflow

2026-09-01

TAK-715 combines nanomolar p38α inhibition with a useful experimental profile for cytokine, inflammation, and rheumatoid arthritis research. This workflow explains how to prepare, dose, validate, and troubleshoot the compound while separating established product data from emerging dual-action mechanistic hypotheses.